Format

Send to

Choose Destination
Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease.

Author information

1
Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address: frank.jessen@ukb.uni-bonn.de.
2
Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
3
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.
4
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
5
Institut des Neurosciences des Systèmes, Université de Marseille, Marseille, France.
6
INSERM, U1077, Caen, France; Université de Caen Basse-Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France.
7
Université Pierre et Marie Curie, Paris, France.
8
INSERM U708, Neuroepidemiology, CIC-EC7 and Bordeaux University, Bordeaux, France.
9
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Australia.
10
Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
11
Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
12
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
13
Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain.
14
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
15
Brooklyn College of The City University of New York, New York, NY, USA; The Graduate Center of The City University of New York, New York, NY, USA.
16
Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA; Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA.
17
Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.
18
Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
19
Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, Australia.
20
Institute of Psychiatry, King's College London, London, UK.
21
Alzheimer's Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
22
Department of Internal Medicine and Geriatrics, Toulouse University Hospital, UMR INSERM 1027, University Paul Sabatier, Toulouse, France.
23
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
24
Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Abstract

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.

KEYWORDS:

Alzheimer's disease; Mild cognitive impairment; Preclinical Alzheimer's disease; Prodromal Alzheimer 's disease; Research criteria; Subjective cognitive decline

PMID:
24798886
PMCID:
PMC4317324
DOI:
10.1016/j.jalz.2014.01.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center